Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 7/20 | 0.49 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.49 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1114104 | 1.00 | BCL2 (0.49) | BCL2BCL2L1BAK1HTR7 | |
| SCHEMBL10058377 | 0.90 | BCL2 (0.51) | BCL2BCL2L1BAK1HTR7 | |
| SCHEMBL19145578 | 0.76 | HTR7 (0.81) | BCL2BCL2L1BAK1HTR7 | |
| SCHEMBL1677378 | 0.75 | HTR7 (0.50) | BCL2BCL2L1BAK1HTR7 | |
| SCHEMBL12806160 | 0.75 | BCL2 (0.50) | BCL2BCL2L1BAK1HTR7 | |
| SCHEMBL1114117 | 0.74 | MEN1 (0.45) | — | |
| SCHEMBL2388437 | 0.71 | BCL2 (0.71) | BCL2BCL2L1BAK1 | |
| SCHEMBL1569401 | 0.71 | TP53 (0.72) | HTR7 | |
| SCHEMBL19014647 | 0.71 | BCL2 (0.64) | BCL2BCL2L1BAK1HTR7 | |
| SCHEMBL376898 | 0.71 | HTR7 (0.60) | BCL2BCL2L1BAK1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAELL JONATHAN BAYLDON | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAX, API5, BCL2 | BCL2 3/4885BCL2L1 13/4885BAK1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.